multiple myeloma
Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial
July 11, 2023Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma
Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …
Janssen submits MAA to EMA for novel CAR-T cell therapy
May 5, 2021Research and Development EMA, EU, Janssen, multiple myeloma
Janssen have submitted a Marketing Authorisation Application (MAA) to the EMA seeking approval of cilta-cel, an investigational B cell maturation …
New Sanofi Sarclisa treatment for multiple myeloma approved by FDA
April 1, 2021FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …
NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma
October 16, 2020Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
FDA committee backs GSK’s belantamab mafodotin in relapsed or refractory multiple myeloma
July 15, 2020Research and Development, Sales and Marketing Cancer, FDA, GSK, multiple myeloma, pharma
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …
100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows
May 14, 2020Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma
Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …
Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma
March 11, 2020Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma
Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …
Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma
Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
FDA fast-tracks GSK’s multiple myeloma drug after priority review
January 22, 2020Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma
The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …
Myeloma UK reveals new Director of Research appointment
November 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myleoma UK, appointment, multiple myeloma, pharma
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role …
Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma
November 8, 2019Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
Amgen’s Kyprolis + Darzalex combo shows progression-free survival benefit in multiple myeloma
September 16, 2019Research and Development, Sales and Marketing Amgen, Kyrpolis, darzalex, multiple myeloma, pharma
Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the …
FDA approves multiple myeloma therapy Xpovio despite safety concerns
July 4, 2019Sales and Marketing FDA, Karyopharm, Xpovio, multiple myeloma, pharma
The FDA has made the controversial decision to approve the nuclear export inhibitor Xpovio (selinexor) from Karyopharm Therapeutics, in combination …
Darzalex combo makes strong Phase 3 showing in multiple myeloma
June 4, 2019Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma
Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …
Isatuximab improves on standard of care treatments for multiple myeloma
June 3, 2019Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma
Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
